AzurRx BioPharma Inc AZRX:NASDAQ

RT Quote | NASDAQ | USD
Last | 03/08/21 EST
1.21UNCH (UNCH)
Volume
1,233,448
52 week range
0.37 - 2.63

...

Loading . . .

KEY STATS

  • Open1.22
  • Day High1.31
  • Day Low1.18
  • Prev Close1.21
  • 52 Week High2.63
  • 52 Week High Date01/22/21
  • 52 Week Low0.37
  • 52 Week Low Date03/12/20
  • Market Cap64.64M
  • Shares Out53.42M
  • 10 Day Average Volume1.98M
  • Dividend-
  • Dividend Yield-
  • Beta1.71
  • 1 Year % Change55.11

RATIOS/PROFITABILITY

  • EPS (TTM)-0.88
  • P/E (TTM)-1.37
  • Fwd P/E (NTM)-2.83
  • EBITDA (MRQ)-9.594M
  • ROE (MRQ)-286.19%
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date03/18/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest AzurRx BioPharma Inc News

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
AzurRx BioPharma, Inc. is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant...
Edward Borkowski CPA
Chairman
James Sapirstein
President
Daniel Schneiderman
Chief Financial Officer
Address
1615 SOUTH CONGRESS AVENUE, SUITE 103
Delray Beach, FL
33445
United States